Paper39028186
Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations.
Heisler J and 4 others. MAbs, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations. Papers, record 39028186. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39028186
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Trastuzumab | Major topic |
| Omalizumab | Major topic |
| Immunoglobulin Fc Fragments | Major topic |
| Immunoglobulin G | Major topic |
| Mutation | Major topic |
| Humans | |
| Viscosity | |
| Immunoglobulin Fab Fragments |
Source PubMed
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33834944 | Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters. | MAbs | 2021 | https://conductscience.org/library/papers/33834944 | PubMed |
| 2 | 11160318 | Engineered antibodies with increased activity to recruit complement. | J Immunol | 2001 | https://conductscience.org/library/papers/11160318 | PubMed |
| 3 | 24737331 | Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering. | J Biol Chem | 2014 | https://conductscience.org/library/papers/24737331 | PubMed |
| 4 | 19250681 | Structural characterization of a human Fc fragment engineered for extended serum half-life. | Mol Immunol | 2009 | https://conductscience.org/library/papers/19250681 | PubMed |
| 5 | 36109838 | Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. | MAbs | 2022 | https://conductscience.org/library/papers/36109838 | PubMed |
| 6 | 26849155 | Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure. | Mol Pharm | 2016 | https://conductscience.org/library/papers/26849155 | PubMed |
| 7 | 23744091 | Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). | Protein Eng Des Sel | 2013 | https://conductscience.org/library/papers/23744091 | PubMed |
| 8 | 17368483 | Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. | J Mol Biol | 2007 | https://conductscience.org/library/papers/17368483 | PubMed |
| 9 | 38853585 | Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling. | MAbs | 2024 | https://conductscience.org/library/papers/38853585 | PubMed |
| 10 | 17875730 | Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. | Cancer Res | 2007 | https://conductscience.org/library/papers/17875730 | PubMed |
| 11 | 25559441 | Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. | MAbs | 2015 | https://conductscience.org/library/papers/25559441 | PubMed |
| 12 | 19705420 | Specific interactions in high concentration antibody solutions resulting in high viscosity. | J Pharm Sci | 2010 | https://conductscience.org/library/papers/19705420 | PubMed |
| 13 | 34747330 | Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions. | MAbs | 2021 | https://conductscience.org/library/papers/34747330 | PubMed |
| 14 | 9231898 | Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. | J Mol Biol | 1997 | https://conductscience.org/library/papers/9231898 | PubMed |
| 15 | 1560463 | Antibody framework residues affecting the conformation of the hypervariable loops. | J Mol Biol | 1992 | https://conductscience.org/library/papers/1560463 | PubMed |
| 16 | 18723496 | Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18723496 | PubMed |
| 17 | 33789155 | A review of Formulations of Commercially Available Antibodies. | J Pharm Sci | 2021 | https://conductscience.org/library/papers/33789155 | PubMed |
| 18 | 26736022 | Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development. | MAbs | 2016 | https://conductscience.org/library/papers/26736022 | PubMed |
| 19 | 26574392 | Long-Time-Step Molecular Dynamics through Hydrogen Mass Repartitioning. | J Chem Theory Comput | 2015 | https://conductscience.org/library/papers/26574392 | PubMed |
| 20 | 33346034 | Machine Learning Feature Selection for Predicting High Concentration Therapeutic Antibody Aggregation. | J Pharm Sci | 2021 | https://conductscience.org/library/papers/33346034 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42533550 | Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies. | MAbs | 2026 | https://conductscience.org/library/papers/42533550 | PubMed |
| 41899522 | Biophysical and Structural Characterization of Antibody-Drug Conjugates. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899522 | PubMed |
| 41875154 | Fab-Fc and Fab-Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgG1 antibodies. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41875154 | PubMed |
| 40888155 | Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study. | MAbs | 2025 | https://conductscience.org/library/papers/40888155 | PubMed |
| 40775487 | Fifty years of monoclonals: the past, present and future of antibody therapeutics. | Nat Rev Immunol | 2025 | https://conductscience.org/library/papers/40775487 | PubMed |
| 40683793 | TREM2 and LAG-3 in cancer and Alzheimer's disease immunotherapy. | Trends Pharmacol Sci | 2025 | https://conductscience.org/library/papers/40683793 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| IGHE | 3497 | PubTator's text mining | https://conductscience.org/library/genes/3497 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39028186
GET https://conductscience.org/api/papers/v1/39028186/references?page=2